Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Stockholders' Equity (Deficit)

v3.20.1
Consolidated Statement of Stockholders' Equity (Deficit) - USD ($)
Common Stock [Member]
Additional Paid-In Capital [Member]
Subscriptions Receivable [Member]
Subscriptions Payable [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Deficit [Member]
Noncontrolling Interest [Member]
Total
Balance at Mar. 26, 2018
Balance, shares at Mar. 26, 2018              
Common stock sold for cash $ 23,412 978,703 (602) 1,001,513
Common stock sold for cash, shares 23,411,905              
Common stock issued for services $ 680 284,920 285,600
Common stock issued for services, shares 680,000              
Contributed capital 136,440 136,440
Consolidation of One World Pharma, Inc. (349,420) (349,420)
Common stock issued for purchase of One World Pharma S.A.S. $ 10,200 152,709 162,909
Common stock issued for purchase of One World Pharma S.A.S., shares 10,200,000              
Beneficial conversion feature on convertible note 75,000 75,000
Loss on foreign currency translation (4,090) $ (4,090)
Cashless exercise of common stock options, shares              
Net loss (1,959,982) (101) $ (1,960,083)
Balance at Dec. 31, 2018 $ 34,292 1,278,352 (602) (4,090) (1,959,982) (101) (652,131)
Balance, shares at Dec. 31, 2018 34,291,905              
Common stock sold for cash $ 8,260 4,122,090 250,000 4,380,350
Common stock sold for cash, shares 8,260,700              
Common stock issued for services $ 100 236,460 236,560
Common stock issued for services, shares 99,666              
Beneficial conversion feature on convertible note 332,332 332,332
Loss on foreign currency translation (12,158) (12,158)
Cash received on subscriptions receivable 602 602
Common stock sold to CEO, debt cancelled in lieu of cash payment $ 400 199,600 200,000
Common stock sold to CEO, debt cancelled in lieu of cash payment, shares 400,000              
Cashless exercise of common stock options $ 51 (51)
Cashless exercise of common stock options, shares 51,040             58,331
Common stock issued on debt conversions $ 1,253 500,144 $ 501,397
Common stock issued on debt conversions, shares 1,253,493              
Amortization of common stock options issued for services 1,402,635 1,402,635
Amortization of common stock options issued for services, OWP Ventures, Inc. 88,297 88,297
Exchange of OWP Ventures, Inc. shares for One World Pharma, Inc. shares (1:1) $ 1,323 (10,730) 101 (9,306)
Exchange of OWP Ventures, Inc. shares for One World Pharma, Inc. shares (1:1), shares 1,322,501              
Common stock cancelled pursuant to merger with OWP Ventures, Inc. $ (875) 875
Common stock cancelled pursuant to merger with OWP Ventures, Inc., shares (875,000)              
Net loss (6,207,184) (6,207,184)
Balance at Dec. 31, 2019 $ 44,483 $ 8,150,004 $ 250,000 $ (16,248) $ (8,167,166) $ 261,394
Balance, shares at Dec. 31, 2019 44,804,305